Cas No.Product NameDescription
1013101-36-4PF-04691502PF-04691502 is an ATP-competitive PI3K/mTOR dual inhibitor with IC50 of 32 nM.
937174-76-0GSK690693GSK-690693 is an ATP-competitive pan-Akt kinase inhibitor (IC50 values are 2, 13 and 9 nM for Akt1, 2 and 3 respectively).
1032350-13-2MK-2206 2HClMK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed.
857531-00-1AT7867AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.
552325-73-2A-674563A-674563 is a potent selective protein kinase B/Akt inhibitor with an IC50 of 14 nM.
1191951-57-1PHT-427PHT-427 is a dual Akt and PDPK1 inhibitor (high affinity binding for the PH domains of Akt and PDPK1) with Ki of 2.7 μM and 5.2 μM, respectively.
885499-61-6CCT128930CCT128930 is a novel potent ATP-competitive, AKT inhibitor with an IC50 of 6 nM.
61966-08-3Triciribine phosphateTriciribine is a DNA synthesis inhibitor, also inhibits Akt and HIV-1 with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase.
1001264-89-6IpatasertibGDC-0068 is a novel, highly selective oral ATP-competitive inhibitor designed to bind to the 3 isoforms of Akt.
58066-85-6MiltefosineMiltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral drug for Visceral leishmaniasis, effective against both promastigotes and amastigotes.
93479-97-1GlimepirideGlimepiride (Hoe 490) is a new sulfonylurea
1047644-62-1AfuresertibAfuresertib is an orally available, ATP-competitive, pan-AKT inhibitor with Ki of 0.08, 2 and 2.6 nM against AKT1, AKT2 and AKT3, respectively.
1047634-63-8GSK2110183GSK2110183 is an orally bioavailable, selective, ATP-competitive and potent pan-Akt inhibitor with IC50s of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively.
305834-79-1SC79SC79 is a unique specific Akt activator that may be used to enhance Akt activity in various physiological and pathological conditions. SC-79 is an activator of Akt that blocks its membrane translocation while allowing its phosphorylation, in the cytosol, by upstream kinases.
1386874-06-1LY3023414LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK, extracted from patent WO/2012097039A1, compound example 1, has an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1(pT308), Akt1 (pS473), P70S6(pT389), S6RP(pS240/242).
1004990-28-6AKT inhibitorAKT inhibitor is a broadly selective, potent, ATP-competitive Akt inhibitor, displays 900-fold greater selectivity for PKBα (IC50 = 0.5 nM) than PKA (IC50=450 nM).
871361-88-5SC 66SC66 is a novel AKT inhibitor, IC50 values of approximately 0.75 μg/ml at 72 hours in HepG2, HA22T/VGH and PLC/PRF/5 cells.
1047645-82-8Afuresertib hydrochlorideAfuresertib Hcl (GSK2110183 Hcl) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma.
1313881-70-7ARQ-092ARQ-092 is an Akt inhibitor extracted from patent US/20150299195A1, compound A.
799264-47-4Nodinitib-1Afuresertib is an orally available, ATP-competitive, pan-AKT inhibitor with Ki of 0.08, 2 and 2.6 nM against AKT1, AKT2 and AKT3, respectively.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway